Bristol-Myers Squibb Co vs GraniteShares 2x Long COIN Daily ETF — how do they compare? Bristol-Myers Squibb Co trades at $63.7 (market cap $129.94B), while GraniteShares 2x Long COIN Daily ETF trades at $4.15. The key difference: Bristol-Myers Squibb Co pays a 3.96% dividend while GraniteShares 2x Long COIN Daily ETF pays none, and Bristol-Myers Squibb Co is trading nearer its 52-week high, GraniteShares 2x Long COIN Daily ETF nearer its low. Which is the better fit depends on your goals.
| BMY | CONL | |
|---|---|---|
Market Cap | $129.94B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $65.89 | $48.70 |
52-Week Low | $42.60 | $3.93 |
Enterprise Value | $163.92B | — |
Dividend Yield | 3.96% | — |
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $63.88, down 1.48% on the day, with strong technical momentum indicated by bullish moving averages and ADX signals. The company demonstrates robust fundamentals with a 14.01 P/E ratio, 18.87% net income margin, and consistent earnings beats in recent quarters. Recent developments include a $2.3 billion manufacturing investment in Houston and strategic AI collaboration with Schrödinger.
BMY presents a compelling investment case with attractive valuation metrics and strong profitability, though investors face risks from patent expirations and debt levels. Analyst consensus suggests 7% upside to the $68.56 price target, with the stock offering dividend income alongside growth potential from pipeline developments and potential M&A activity.
CONL, the GraniteShares 2x Long COIN Daily ETF, trades at $4.11, up 0.49% on the day but reflecting a bearish technical signal with moving averages indicating strong selling pressure. The ETF has experienced significant volatility and value erosion, with news highlighting a 67% year-to-date loss as of June 2026 due to the daily-reset leverage structure amplifying Coinbase's price swings. Key financial ratios are not applicable as this is a leveraged ETF tracking another security.
Outlook remains highly speculative and risky due to the ETF's daily leverage, which can lead to rapid losses in volatile markets. Investment opportunity is limited to short-term traders betting on Coinbase rallies, but risks include volatility decay, tracking error, and dependence on Coinbase performance. Long-term holding is discouraged by the structure's inherent erosion.
Trailing returns across standard periods
Latest headlines on both assets
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →CONL is a leveraged ETF that seeks to provide two times (2x) the daily performance of Coinbase Global (COIN) stock. It is designed for investors seeking magnified short-term exposure to the price movements of Coinbase.
Read more on CONL →